Patents by Inventor Pingyu Ding

Pingyu Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPIOID RECEPTOR MODULATORS
    Publication number: 20240092746
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: February 13, 2023
    Publication date: March 21, 2024
    Inventors: Julio Cesar MEDINA, Alok NERURKAR, Corinne SADLOWSKI, Frederick SEIDL, Heng CHENG, Jason DUQUETTE, John LEE, Martin HOLAN, Pingyu DING, Xiaodong WANG, Tien WIDJAJA, Thomas NGUYEN, Ulhas BHATT, Yihong LI, Zhi-liang WEI
  • Tyrosine kinase inhibitors
    Patent number: 11672791
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: June 13, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • Opioid receptor modulators
    Patent number: 11634396
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: April 25, 2023
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Alok Nerurkar, Corinne Sadlowski, Frederick Seidl, Heng Cheng, Jason Duquette, John Lee, Martin Holan, Pingyu Ding, Xiaodong Wang, Tien Widjaja, Thomas Nguyen, Ulhas Bhatt, Yihong Li, Zhi-liang Wei
  • 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF
    Publication number: 20230123856
    Abstract: Provided herein is a compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, Y, X, and n are defined herein. Also provided herein are compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of heart disease.
    Type: Application
    Filed: April 4, 2022
    Publication date: April 20, 2023
    Applicant: Tenaya Therapeutics, Inc.
    Inventors: Mohammad A. MANDEGAR, Snahel PATEL, Ulhas BHATT, Pingyu DING, Martin HOLAN, John LEE, Yihong LI, Julio MEDINA, Alok NERURKAR, Frederick SEIDL, David SPERANDIO, Tien WIDJAJA, Xiaodong WANG
  • TYROSINE KINASE INHIBITORS
    Publication number: 20230012676
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 19, 2023
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • OPIOID RECEPTOR MODULATORS
    Publication number: 20220356157
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: April 5, 2022
    Publication date: November 10, 2022
    Inventors: Julio Cesar MEDINA, Alok NERURKAR, Corinne SADLOWSKI, Frederick SEIDL, Heng CHENG, Jason DUQUETTE, John LEE, Martin HOLAN, Pingyu DING, Xiaodong WANG, Tien WIDJAJA, Thomas NGUYEN, Ulhas BHATT, Yihong LI, Zhi-liang WEI
  • Opioid receptor modulators and products and methods related thereto
    Patent number: 11352316
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: June 7, 2022
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Lawrence R McGee, Zhi-Liang Wei, Corinne Sadlowski, Frederick Seidl, Ulhas Bhatt, Xiaodong Wang, Thomas Nguyen, David Sperandio, Pingyu Ding, Alok Nerurkar, Yihong Li, Jason Duquette
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20220024907
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 11174251
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: November 16, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • TGF-ß INHIBITORS
    Publication number: 20210276982
    Abstract: Disclosed are aryl pyrimidine compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, R and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 9, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Marina Gelman, Pingyu Ding, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Jeffrey Clough
  • Tyrosine kinase inhibitors
    Patent number: 11110082
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: September 7, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20210163402
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Application
    Filed: July 10, 2020
    Publication date: June 3, 2021
    Inventors: Julio Cesar Medina, Lawrence R McGee, Zhi-Liang Wei, Corinne Sadlowski, Frederick Seidl, Ulhas Bhatt, Xiaodong Wang, Thomas Nguyen, David Sperandio, Pingyu Ding, Alok Nerurkar, Yihong Li, Jason Duquette
  • TGF-ß inhibitors
    Patent number: 11021468
    Abstract: Disclosed are aryl pyrimidine compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, R and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: June 1, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Marina Gelman, Pingyu Ding, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Jeffrey Clough
  • OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20210147343
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulate the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Application
    Filed: April 4, 2019
    Publication date: May 20, 2021
    Inventors: Julio Cesar MEDINA, Larry McGEE, Zhi-Liang WEI, Corinne SADLOWSKI, Frederick SEIDL, Ulhas BHATT, Xiaodong WANG, Thomas NGUYEN, David SPERANDIO, Pingyu DING, Alok NERURKAR, Yihong LI, Jason DUQUETTE
  • 2,3-Disubstituted pyridine compounds as TGF-? inhibitors and methods of use
    Patent number: 10858335
    Abstract: The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds inhibit signaling by a member of the TGF-? superfamily such as Nodal or Activin.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: December 8, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20200115371
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Application
    Filed: October 17, 2019
    Publication date: April 16, 2020
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • TYROSINE KINASE INHIBITORS
    Publication number: 20200078348
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 12, 2020
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 10479783
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • Tyrosine kinase inhibitors
    Patent number: 10434096
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: October 8, 2019
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use
    Publication number: 20190284155
    Abstract: The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer.
    Type: Application
    Filed: January 16, 2019
    Publication date: September 19, 2019
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella